Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.06 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: dasatinib anhydrous, vandetanib, ilorasertib +8 | 1.00 |
| trials ClinicalTrials.gov | 3 Parkinson's trials, 0 stopped | 1.00 |
| literature PubMed | 112 Parkinson's papers of 38,127 | 0.38 |
| pathways Reactome | 70 pathways; mostly mitochondrial quality control | 1.00 |
No case: the score is under the bar. Receipt 4744
Sealed predictions
- SRC in dopamine neurons, braak-0.35 (p 0.362) → -0.37 (p 0.334)receipt 4750
Swarm cases
receipt 4750: SRC in dopamine neurons, braak
- power
- full sample -0.33 (p 0.188, n 18), 95% CI -0.69 to +0.17. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.34 (p 0.161, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.42 (p 0.084, n 18). could be the mix.
- skeptic
- leave-one-out range -0.47 to -0.24, sign flips 0; without severely affected donors -0.33 (p 0.188, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SRC in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts